NeuroDiscovery closes IPO
Friday, 12 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) has closed its $1.5 million IPO and completed its acquisition of UK-based NeuroSolutions.
NeuroDiscovery offered 7.5 million shares at an issue price of AUD$0.20 each to raise the $1.5 million. NeuroSolutions - which has a mature pipeline of programs for the treatment of pain - is expected to commence Phase I and II clinical trials in the next 18 months.
NeuroDiscovery expects to list on the ASX on Monday 15 August.
TGA approves first treatment for geographic atrophy
Australia has become the first country outside of the United States to approve the use of the...
Damaged RNA, not DNA, revealed as main cause of acute sunburn
Sunburn has traditionally been attributed to UV-induced DNA damage, but it turns out that this is...
Multi-ethnic studies identify new genes for depression
Two international studies have revealed hundreds of previously unknown genetic links to...
